SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread inflammation and organ damage, driven by a complex interplay of genetic predisposition, environmental factors, and immune dysregulation.¹ Current therapeutic approaches, primarily corticosteroids and broad immunosuppressants, often achieve disease control but are associated with significant adverse effects and fail to induce sustained remission in a substantial proportion of patients.² The clinical dilemma lies in the lack of precise tools to predict treatment response and tailor therapy to individual patient needs, leading to a trial-and-error approach that can delay effective disease management and accumulate damage.³

Advances in Pathophysiology and Precision Care

Presentations at EULAR 2026 focused on dissecting the intricate immunological pathways driving SLE, moving beyond a generalized understanding to identify specific molecular and cellular endotypes. A central theme was the role of type I interferons (IFN-I) in SLE pathogenesis. Elevated IFN-I signatures are present in a significant subset of SLE patients, correlating with disease activity and specific clinical manifestations, such as skin rash and nephritis.⁴ Studies presented detailed the upstream activators of IFN-I pathways, including nucleic acid-sensing receptors like Toll-like receptors (TLR7 and TLR9) and STING, which recognize self-DNA and RNA.⁵ This enhanced understanding has directly informed the development of therapies targeting the IFN-I pathway, such as anifrolumab, a monoclonal antibody against the type I interferon receptor.⁶

Beyond IFN-I, significant attention was given to B-cell dysregulation. While B-cell depletion with rituximab has shown mixed results in SLE trials, newer insights highlight the importance of specific B-cell subsets and their interactions with T cells.⁷ For instance, the role of plasma cells in autoantibody production and the survival factors that sustain them, such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), were discussed.⁸ Belimumab, a BAFF inhibitor, has demonstrated efficacy in reducing disease activity and preventing flares in a broad SLE population.⁹ Further research presented at EULAR 2026 explored the potential for targeting specific B-cell subpopulations, such as activated B cells or plasmablasts, which may offer more precise therapeutic interventions than pan-B-cell depletion.¹⁰

The concept of disease endotypes, defined by distinct molecular signatures, emerged as a cornerstone for future precision care. Researchers presented data on stratifying SLE patients based on their IFN-I signature, allowing for the identification of individuals most likely to respond to IFN-I pathway inhibitors.¹¹ Similarly, analyses of gene expression profiles and proteomic data from patient cohorts are beginning to delineate other endotypes, such as those driven predominantly by neutrophil extracellular traps (NETs) or specific cytokine profiles (e.g., IL-6, IL-10).¹² The goal is to match specific therapies to these endotypes, moving away from a 'one-size-fits-all' approach. For example, a patient with a high IFN-I signature and active nephritis might be a candidate for an IFN-I receptor antagonist, while a patient with predominantly joint involvement and a different cytokine profile might benefit from an alternative targeted agent.¹³

Limitations in current research include the challenge of validating these endotypes in large, diverse patient cohorts and developing accessible, reliable biomarkers for routine clinical use. While gene expression profiling offers high resolution, its practicality in a busy clinical setting remains a hurdle.¹⁴ Future directions involve integrating multi-omics data (genomics, transcriptomics, proteomics, metabolomics) with clinical phenotypes to refine endotype classification. The development of companion diagnostics to identify responders to specific targeted therapies is also a critical next step.¹⁵ The ultimate aim is to implement a precision medicine framework where treatment decisions for SLE are guided by individual patient biology, optimizing efficacy and minimizing adverse effects.